Fluvastatin inhibits HMG-CoA reductase and prevents non-small cell lung carcinogenesi

Tianshun Zhang, Ruihua Bai, Qiushi Wang, Keke Wang, Xiang Li, Kangdong Liu, Joohyun Ryu, Ting Wang, Xiaoyu Chang, Weiya Ma, Ann M. Bode, Qingxin Xia, Yongping Song, Zigang Dong

Research output: Contribution to journalArticle


Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinical applications. In this study, we found that fluvastatin targeted 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), which a rate-limiting enzyme in the mevalonate pathway, and inhibited non-small cell lung cancer (NSCLC) tumorigenesis. Initially, we demonstrated that HMGCR is overexpressed in human lung adenocarcinoma tissues compared with normal tissues. Knockdown of HMGCR in NSCLC cells attenuated growth and induced apoptosis in vitro and in vivo. Furthermore, we found that fluvastatin, an inhibitor of HMGCR, suppressed NSCLC cell growth and induced apoptosis. Intriguingly, fluvastastin functions by inhibiting the HMGCR-driven Braf/MEK/ERK1/2 and Akt signaling pathways. Notably, fluvastatin attenuated tumor growth in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis and in a patient-derived xenograft lung tumor model. Overall, our findings suggest that fluvastatin might be promising chemopreventive or potential therapeutic drug against NSCLC tumorigenesis, providing hope for rapid clinical translation.

Original languageEnglish (US)
Pages (from-to)837-848
Number of pages12
JournalCancer Prevention Research
Issue number12
StatePublished - Jan 1 2019

Fingerprint Dive into the research topics of 'Fluvastatin inhibits HMG-CoA reductase and prevents non-small cell lung carcinogenesi'. Together they form a unique fingerprint.

  • Cite this